We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




X-ray Crystallography Study May Lead to New Drugs to Block Cancer Metastasis

By LabMedica International staff writers
Posted on 28 Apr 2016
Cancer researchers expect that the structure of the enzyme P-Rex1 (PIP3-dependent Rac exchanger 1), which was recently established by X-ray crystallography, will lead to development of a new generation of cancer chemotherapeutic agents to block the processes leading to metastasis.

P-Rex1 is a Rho guanine nucleotide exchange factor synergistically activated by the lipid PIP3 (phosphatidylinositol 3,4,5-trisphosphate) that plays an important role in the metastasis of breast, prostate, and skin cancer, which makes it an attractive therapeutic target. More...
However, the molecular mechanisms behind P-Rex1 regulation have been poorly understood.

Investigators at the University of Michigan (Ann Arbor, USA) used X-ray crystallography to determine structures of the P-Rex1 pleckstrin homology domain (a protein domain of approximately 120 amino acids that occurs in a wide range of proteins involved in intracellular signaling) bound to the headgroup of PIP3.

They reported in the April 14, 2016, online edition of the journal Structure that PIP3 binding to the pleckstrin homology domain was required for P-Rex1 activity in cells but not for membrane localization, which pointed to an allosteric activation mechanism by PIP3.

"P-Rex1 has been an attractive drug target for some time," said senior author Dr. John J.G. Tesmer, professor of pharmacology and biological chemistry at the University of Michigan. "But development of these drugs has been hindered by a lack of understanding of its structure and regulatory mechanisms. Our data have confirmed the location of the binding site, which will greatly assist with the identification or design of small molecules that target this mechanism of activation."

Related Links:
University of Michigan


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.